•EBV-negative Burkitt lymphoma relies on oncogenic mutations in the ARF-MDM2-TP53 apoptotic pathway, while EBV-positive Burkitt lymphoma gains anti-apoptotic activity as a direct effect of EBV on apoptotic pathways. Here, CDKN2A is linked to Burkitt lymphoma.